Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06219629 · ClinicalTrials.gov registry record
Parkinson's Disease Progression Study
A clinical trial of Parkinson Disease, sponsored by Koneksa Health.
- Active
- Registry status
- 82
- Enrollment target
- 10
- Study locations
NCT06219629: Active study of Parkinson Disease, sponsored by Koneksa Health.
NCT06219629 is a study of Parkinson Disease that is active but no longer recruiting, run by Koneksa Health. The registered enrollment target is 82 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06219629, a study of Parkinson Disease, is active but no longer recruiting, sponsored by Koneksa Health.
- ACTIVE NOT RECRUITING
- Registry status
- 82 participants
- Enrollment target
- 10
- Study locations
Study Summary
Disease Progression Study
Primary Outcome
Percentage of total toolkit tasks completed during the remote data collection period
Conditions Studied
Study Locations (10)
Florida
- Parkinsons Disease And Movement Disorders Center Of Boca Raton - Boca Raton
- Accel Research Sites DeLand - DeLand
- Accel Research Sites St Petersburg-Largo - Largo
- N1 Research LLC - Orlando
Colorado
- University of Colorado Health Neurosciences Center - Aurora
Georgia
- Augusta University Health Movement Disorder Clinic - Augusta
Kansas
- University of Kansas Medical Center Parkinson's Disease and Movement Disorder Center - Kansas City
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Michigan
- Quest Research Institute - Farmington Hills
Nevada
- Cleveland Clinic - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2024-02-20 |
| Est. Completion | 2026-02 |
What the registry record for NCT06219629 still lists
NCT06219629 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 0 interventions.
NCT06219629 lists 10 locations in 7 states (Florida, Colorado, Georgia).
Frequently Asked Questions
What is clinical trial NCT06219629 about?
NCT06219629 is a clinical study titled "Parkinson's Disease Progression Study". Disease Progression Study
What is the current status of trial NCT06219629?
This trial is currently active not recruiting. The enrollment target is 82 participants. The study started on 2024-02-20. Estimated completion is 2026-02.
What conditions does trial NCT06219629 study?
This clinical trial studies the following conditions: Parkinson Disease.
Who is sponsoring clinical trial NCT06219629?
This trial is sponsored by Koneksa Health, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06219629 being conducted?
This trial has 10 study locations across Colorado, Florida, Georgia, Kansas, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06219629's enrollment target sits among peer trials
82 102nd of 297 higher than 195 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI